Figure 1 from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer

Key Points

• The study assesses the clinical validity of the FoundationOne Liquid CDx for BRAF V600E detection in colorectal cancer, with promising implications for personalized treatment.
• Key evidence includes testing concordance with the Qiagen Therascreen BRAF V600E PCR Kit, ensuring accuracy in identifying mutations.
• Utilizing a sample processing flow chart, the methodology incorporates library construction, quality control, and sequencing techniques for precise diagnostics.
• These findings support the use of advanced liquid biopsy technologies, emphasizing the potential for improved patient management in colorectal cancer.